CN104603127B - 补体途径调节剂及其应用 - Google Patents

补体途径调节剂及其应用 Download PDF

Info

Publication number
CN104603127B
CN104603127B CN201380035327.6A CN201380035327A CN104603127B CN 104603127 B CN104603127 B CN 104603127B CN 201380035327 A CN201380035327 A CN 201380035327A CN 104603127 B CN104603127 B CN 104603127B
Authority
CN
China
Prior art keywords
methyl
base
benzo
indole
imidazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380035327.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104603127A (zh
Inventor
C·M·亚当斯
C·巴布
J·丁
江原建
K·珍德扎
N·嵇
R·G·卡尔基
川波纪雄
L·薛
N·马伊诺尔菲
J·J·鲍尔斯
M·H·塞拉诺-武
C·张
M·P·卡帕雷利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104603127(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104603127A publication Critical patent/CN104603127A/zh
Application granted granted Critical
Publication of CN104603127B publication Critical patent/CN104603127B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380035327.6A 2012-05-04 2013-05-03 补体途径调节剂及其应用 Expired - Fee Related CN104603127B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261642798P 2012-05-04 2012-05-04
US61/642,798 2012-05-04
US201361782820P 2013-03-14 2013-03-14
US61/782,820 2013-03-14
PCT/IB2013/053546 WO2013164802A1 (en) 2012-05-04 2013-05-03 Complement pathway modulators and uses thereof

Publications (2)

Publication Number Publication Date
CN104603127A CN104603127A (zh) 2015-05-06
CN104603127B true CN104603127B (zh) 2016-10-05

Family

ID=48626502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035327.6A Expired - Fee Related CN104603127B (zh) 2012-05-04 2013-05-03 补体途径调节剂及其应用

Country Status (25)

Country Link
EP (1) EP2855456B1 (enExample)
JP (1) JP6180514B2 (enExample)
KR (1) KR20150003903A (enExample)
CN (1) CN104603127B (enExample)
AP (1) AP2014008040A0 (enExample)
AR (1) AR090945A1 (enExample)
AU (1) AU2013255470B2 (enExample)
BR (1) BR112014027359A2 (enExample)
CA (1) CA2872000A1 (enExample)
CL (1) CL2014002919A1 (enExample)
CR (1) CR20140508A (enExample)
EA (1) EA027113B1 (enExample)
ES (1) ES2630079T3 (enExample)
HK (1) HK1206017A1 (enExample)
IL (1) IL235362A0 (enExample)
MX (1) MX2014013428A (enExample)
PE (1) PE20150623A1 (enExample)
PH (1) PH12014502462A1 (enExample)
PL (1) PL2855456T3 (enExample)
PT (1) PT2855456T (enExample)
SG (1) SG11201406973PA (enExample)
TN (1) TN2014000449A1 (enExample)
TW (1) TW201348199A (enExample)
UY (1) UY34781A (enExample)
WO (1) WO2013164802A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143638A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
CN103755622A (zh) * 2013-12-25 2014-04-30 华东理工大学 合成4,5,6,7-四氘代吲哚-3-乙酸的方法
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
TWI854164B (zh) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
KR20190036520A (ko) * 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TW202535858A (zh) 2018-04-06 2025-09-16 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
WO2021204801A1 (en) * 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
US20230331710A1 (en) 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN118108700A (zh) * 2020-08-07 2024-05-31 诺华股份有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CN116496249A (zh) 2022-01-26 2023-07-28 上海美悦生物科技发展有限公司 补体因子b抑制剂的盐型、晶型及其制备方法和应用
WO2023187715A1 (en) * 2022-04-01 2023-10-05 Novartis Ag Complement factor b inhibitors and uses thereof
CN118026998A (zh) 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
CN120435467A (zh) * 2022-12-31 2025-08-05 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008453A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1153780A (zh) * 1995-12-06 1997-07-09 拜尔公司 苯并咪唑-异假吲哚
CN1418211A (zh) * 2000-01-17 2003-05-14 帝人株式会社 苯并咪唑衍生物
CN1930133A (zh) * 2004-01-14 2007-03-14 诺瓦提斯公司 苯并咪唑衍生物
CN101072772A (zh) * 2004-10-08 2007-11-14 先灵公司 凝血酶受体拮抗剂
CN101484420A (zh) * 2006-07-03 2009-07-15 比奥维特罗姆上市公司 作为5-ht6调节剂的吲哚
WO2010096314A1 (en) * 2009-02-18 2010-08-26 Amgen Inc. INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
CN102307870A (zh) * 2008-12-09 2012-01-04 诺瓦提斯公司 Vegf-r2的吡啶氧基吲哚类抑制剂及其用于治疗疾病的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB8420919D0 (en) * 1984-08-17 1984-09-19 Beecham Group Plc Compounds
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2007034277A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
MA32975B1 (fr) * 2008-12-22 2012-01-02 Chemocentryx Inc Antagonistes de c5ar
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1153780A (zh) * 1995-12-06 1997-07-09 拜尔公司 苯并咪唑-异假吲哚
CN1418211A (zh) * 2000-01-17 2003-05-14 帝人株式会社 苯并咪唑衍生物
CN1930133A (zh) * 2004-01-14 2007-03-14 诺瓦提斯公司 苯并咪唑衍生物
CN101072772A (zh) * 2004-10-08 2007-11-14 先灵公司 凝血酶受体拮抗剂
CN101484420A (zh) * 2006-07-03 2009-07-15 比奥维特罗姆上市公司 作为5-ht6调节剂的吲哚
CN102307870A (zh) * 2008-12-09 2012-01-04 诺瓦提斯公司 Vegf-r2的吡啶氧基吲哚类抑制剂及其用于治疗疾病的用途
WO2010096314A1 (en) * 2009-02-18 2010-08-26 Amgen Inc. INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS

Also Published As

Publication number Publication date
KR20150003903A (ko) 2015-01-09
IL235362A0 (en) 2014-12-31
TN2014000449A1 (en) 2016-03-30
TW201348199A (zh) 2013-12-01
EP2855456B1 (en) 2017-03-29
PE20150623A1 (es) 2015-05-17
HK1206017A1 (en) 2015-12-31
EA027113B1 (ru) 2017-06-30
UY34781A (es) 2013-12-31
BR112014027359A2 (pt) 2017-07-18
WO2013164802A1 (en) 2013-11-07
AP2014008040A0 (en) 2014-10-31
CL2014002919A1 (es) 2015-07-03
JP6180514B2 (ja) 2017-08-16
PH12014502462A1 (en) 2014-12-22
JP2015515976A (ja) 2015-06-04
AU2013255470B2 (en) 2015-09-17
SG11201406973PA (en) 2014-12-30
ES2630079T3 (es) 2017-08-17
CN104603127A (zh) 2015-05-06
EP2855456A1 (en) 2015-04-08
AR090945A1 (es) 2014-12-17
AU2013255470A1 (en) 2014-11-13
CR20140508A (es) 2015-03-13
MX2014013428A (es) 2015-02-04
PT2855456T (pt) 2017-07-10
PL2855456T3 (pl) 2017-09-29
EA201492023A1 (ru) 2015-03-31
CA2872000A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
CN104603127B (zh) 补体途径调节剂及其应用
CN105229003B (zh) 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
US9056874B2 (en) Complement pathway modulators and uses thereof
TWI476199B (zh) 用於治療疾病之巨環衍生物
CN106458981B (zh) 用于治疗补体介导的疾病的化合物
CN104640855B (zh) 补体途经调节剂及其用途
CN104583196B (zh) 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN103402996B (zh) 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
CN101815713B (zh) 多环化合物
CN105579444B (zh) 哌啶基吲哚衍生物和它们作为补体因子b抑制剂的用途
CN104619698B (zh) 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104684910B (zh) 补体途经调节剂及其用途
CN114230523A (zh) 作为ROR-γ的调节剂的苯并咪唑衍生物
CN105555766A (zh) 作为补体因子d抑制剂的氨基甲基-联芳基衍生物及其应用
CN114746405A (zh) 作为反常破坏剂的新braf抑制剂
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN115413279A (zh) P2x3调节剂
TW201741294A (zh) 以唑基取代的吡啶化合物
CN103842365B (zh) 作为V1a拮抗剂的环己基‑4H，6H‑5‑氧杂‑2，3，10b‑三氮杂‑苯并[e]薁
CN115380030A (zh) 作为sstr4激动剂的n-杂芳基烷基-2-(杂环基和杂环基甲基)乙酰胺衍生物
HK40068409B (zh) 作为反常破坏剂的新braf抑制剂
HK1193601B (en) Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
HK1193601A (en) Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161005

CF01 Termination of patent right due to non-payment of annual fee